Clinical trial · Interventional
Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
15xxGCC: PHASE II TRIAL OF THE EP4 RECEPTOR ANTAGONIST, AAT-007 (RQ-07; CJ-023,423) IN ADVANCED SOLID TUMORS
NCT02538432CI-TRIAL-00041426withdrawnPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): PI No Longer at University of Maryland. Now at Fox Chase
Summary
Brief summary (as posted)
This is a phase II trial of (RQ-07) in advanced solid tumors in prostate, breast or non-small cell lung cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gemcitabine | Drug | Gemcitabine | ALIAS |
| RQ-00000007 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- RQ-00000007 Alone
- description
- RQ-0000007 250 mg will be self-administered orally, with or without food, each morning and evening, approximately 12 hours apart.
- interventionNames
- Drug: RQ-00000007
- type
- ACTIVE_COMPARATOR
- label
- Gemcitabine
- description
- For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be given as an IV.
- interventionNames
- Drug: RQ-00000007
- Drug: Gemcitabine
Primary outcomes (1)
- measure
- Circulating Tumor Cells (CTC)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically or cytologically confirmed breast, prostate or non-small cell lung cancer or other A tissue block, 10 unstained slides or fresh tissue biopsy is required. 2. At least 2 weeks should have elapsed since the last treatment and patients should have recovered from previous significant toxicity (i.e. to grade 1 or less). 3. ECOG Performance Status \<2. 4. Patient at least 18 years of age or older. 5. Adequate hematological function as defined by the protocol, section 4.1.5. 6. Patients must have a serum creatinine within normal limits, or an estimated or measured creatinine clearance \> 35 mg/ml/min. 7. Normal serum electrolytes (no \>grade 2 abnormalities), magnesium and phosphorus on the day of therapy. Correction of abnormalities is permitted. Adequate hepatic function per institutional standards (see exclusion). 8. All patients must be informed of the investigational nature of this study and must sign and give written informed consent. 9. Serum calcium, magnesium and potassium must be within normal limits. Supplementation to achieve normal values is permitted. 10. Patients who are potentially fertile and sexually active must be willing to utilize effective birth control. 11. Patients with CNS metastases which are/were symptomatic must have completed therapy (surgery, gamma knife, XRT) and be neurologically stable. 12. Patients must have \> or = 4 circulating tumor cells Exclusion Criteria: 1. Patients must not have serious infection or other serious underlying medical condition which would impair the ability of the patient to receive protocol treatment. 2. Current uncontrolled cardiac disease 3. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration 4. Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 4 weeks of registration. 5. Patients with acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition or patients known to be HIV positive 6. Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
References
Publications (0)
Data not yet available
No reference posted for this study.